• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
DVAX

DVAX

Dynavax Technologies Corporation

NASDAQHealthcareDrug Manufacturers - Specialty & GenericUS

USD15.50

+0.00 (+0.00%)

Company Profile

CEO

Ryan Spencer

IPO Date

2004-02-19

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Exchange

NASDAQ

Country

US

Market Metrics

Open

$15.50

Prev. Close

$15.50

Day Low

$15.50

Day High

$15.50

52W Low

$9.20

52W High

$15.73

Market Cap

$1.82B

Volume

5.66M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

49.4%

Avg Negative

3.2%

Avg Neutral

47.4%

News Feed

Why Dynavax Stock Is Skyrocketing 45.8% This Week

The Motley Fool·8/27/2021·↑ positive

Why Coronavirus Stock Dynavax Crushed It Today

The Motley Fool·8/23/2021·↑ positive

Powered By Dynavax Adjuvant, Medigen COVID-19 Vaccine Launched In Taiwan

Benzinga·8/23/2021·↑ positive

Dynavax Technologies Corporation (DVAX) CEO Ryan Spencer on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/4/2021·↓ negative

Dynavax Technologies (DVAX) Q2 Earnings and Revenues Top Estimates

Zacks Investment Research·8/4/2021·↑ positive

Dynavax: Earnings This Year Ought To Surprise To The Upside

Seeking Alpha·8/1/2021·↑ positive

Dynavax to Report Second Quarter 2021 Financial Results and Host Conference Call on August 4, 2021

PRNewsWire·7/21/2021·↓ negative

Why Dynavax Stock Has Jumped 11% So Far This Week

The Motley Fool·7/2/2021·↑ positive

Clover, Dynavax Ink Commercial Supply Agreement For CpG 1018 Adjuvant

Benzinga·6/30/2021·↑ positive

Clover and Dynavax Announce Commercial Supply Agreement of Dynavax's CpG 1018 Adjuvant for Clover's COVID-19 Vaccine Candidate

PRNewsWire·6/30/2021·↑ positive